BIOTIE THERAPIES CORP BIOTIE THERAPIES CORP. Stock Exchange Release 1 August 2014 at 10.40 am
Correction to Stock Exchange Release: Change in the number of votes relating to Biotie Therapies Corp.'s shares published 30 July at 8.45 am
Biotie corrects its release published on July 30 regarding change in the number of votes. Corrections relate to the following items: Increase in number of outstanding shares, total amount of voting rights and number of the Company's shares held by the Group. Below is the corrected release in its entirety:
Biotie Therapies Corp. ("Biotie" or the "Company") has conveyed Biotie shares held as treasury shares, that were issued on 2 January 2014, pursuant to the Stock Option Plan 2011 and the Equity Incentive Plan 2011 (the "Plans") as follows:
| Shares conveyed | Cumulative shares conveyed since 2 January 2014 | Remaining shares to be conveyed |
| 1,812,910 | 3,059,160 | 262,500 |
Under the Stock Option Plan 2011, the owners of the stock options may subscribe for a maximum total of 7,401,000 new shares in the Company or existing shares held by the Company. A total of 766,750 shares have been subscribed for during the period 9 May 2014 and 29 July 2014 and 766,750 of the treasury shares will be used for these share subscriptions. The subscription price of EUR 0.01 per share has been fully paid by the employee and the EUR 7,667.50 funds received will be credited to the Company's reserve for non-restricted equity.
The first vesting period of the Equity Incentive Plan 2011 ended on 5 January 2014, after which the Company's shares shall be delivered to employees on the basis of the granted share units. It was resolved pursuant to the authorization of the Annual General Meeting of the Shareholders held on 4 April 2013 to issue 1,046,160 existing treasury shares to the employees without consideration for the purposes of remunerating the employees pursuant to the terms and conditions of the Equity Incentive Plan 2011 and thus, there is an especially weighty financial reason to derogate from the pre-emptive right of the shareholders, as referred to in Chapter 9 Section 4(1) of the Companies Act (624/2006, as amended).
The conveyed shares previously held as treasury shares have not carried any voting rights. The conveyance does not affect the number of registered shares. After the conveyances the changes are as follows:
| Increase in number of outstanding shares | Total amount of voting rights | Number of the Company's share held by the Group | Total number of registered shares |
| 1,812,910 | 449,515,822 | 6,516,576 | 456,032,398 |
Turku, 1 August 2014
Biotie Therapies Corp.
Timo Veromaa, President and CEO
For further information, please contact:
Virve Nurmi, Investor Relations Manager, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com:
mailto:virve.nurmi@biotie.com
www.biotie.com
DISTRIBUTION:
NASDAQ OMX Helsinki Ltd
Main Media
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biotie Therapies Oyj via Globenewswire
